Horus Pharma laboratories launched ODM 5, , the first preservative-free hyperosmolar solution for the management of corneal oedema.
Corneal oedema is a common clinical condition that affects a large part of the population, leading to diagnostic and therapeutic problems. It is characterized by swelling of the cornea due to an accumulation of fluid, especially in the stroma. This excessive accumulation of water causes an increase in corneal thickness and a loss of transparency. The cornea becomes cloudy, causing a loss of visual acuity and a significant decrease in visual comfort, crippling daily due to pervasive symptomatology (fog sensation, perception of halos, photophobia, lacrimation, and pain).
The causes are numerous: congenital (corneal dystrophy) keratalgia, trauma (burn, wound, contusion), eye surgery (refractive surgery, operation)
In France, the most advanced treatment of corneal oedema is corneal grafting, though its prognosis varies depending on the cause of the oedema. Symptomatic treatment of corneal oedema involves, meanwhile, local application of anti-oedema eye drops such as hyperosmolar solutions (sodium chloride base), previously unavailable in France.
The only corneal anti-oedema treatment available in France, ODM 5, is a preservative-free hyperosmolar solution offering a significant improvement in the treatment of corneal oedema.
ODM5 is a medical device with CE marking.
Retail Price: €10.53
Directions for use: 1 to 2 drops 4 times per day
Notice : click here
1 « Cytoprotective Effect of Hyaluronic Acid and Carbomer 934P in Ocular Surface Epithelial Cells ». Caroline Debbasch, Stéphanie Bruneau De La Salle, Françoise Brignole, Patrice Rat, Jean-Michel Warnet, and Christophe Baudouin. Investigative Ophthalmology & Visuel Science, November 2002, Vol. 43., No. 11.
2 « Hyaluronan-induced stimulation of corneal wound healing is a pure pharmacological effect ». Camillieri G, Bucolo C, Rossi S, Drago F. J Ocul Pharmacol Ther. 2004; 20(6):548-53.